elecoglipron

all catalysts(0)

nothing on the calendar yet

News(6)

• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 3d ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 3d ago
• Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
  With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
  biospace · 1mo ago
• AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
  Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…
  biopharma_dive · 2mo ago
• Gilead and Merck’s latest trial success and flop
  AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
  stat · 2mo ago
• STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
  AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
  stat · 2mo ago